<DOC>
	<DOC>NCT01276405</DOC>
	<brief_summary>This observational study will evaluate Xeloda (capecitabine) monotherapy on the effect of disease-free survival in patients with colon cancer stage III (Duke C) after surgical resection. Data will be collected for 3 years.</brief_summary>
	<brief_title>An Observational Study of Xeloda (Capecitabine) Monotherapy in Patients With Colorectal Cancer (AXEL)</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Adult patients, over the age of 18 years Presence of colon adenocarcinoma Surgical resection for colon cancer stage III (Duke C) Prior adjuvant therapy with Xeloda monotherapy Contraindications for Xeloda</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>